Gilead sues Teva over Atripla ANDA
This article was originally published in Scrip
Executive Summary
Gilead Sciences has filed suit in the New York District Court against Teva Pharmaceutical Industries, relating to the latter's generic version of the once-daily triple combination HIV/AIDS product, Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate), thus triggering a 30-month stay of approval while the legal challenge is fought.